Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis [0.03%]
ARID1A突变型和WT型子宫内膜样癌的比较蛋白质组学分析：来自肿瘤图谱网络项目的数据
Susu Zhou,Devashish Desai,Noriko Kishi et al.
Susu Zhou et al.
Background: PARP inhibitor (PARPi)-based therapy is a well-established treatment modality for metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) deficiencies. However, ...
Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis [0.03%]
关于眼脉络膜黑色素瘤转移灶中特班他富单抗的系统评价和 meta 分析
Erick F Saldanha,Mariana M Noronha,Pedro C A Reis et al.
Erick F Saldanha et al.
Background: Tebentafusp is the first systemic therapy to improve survival outcomes for patients with HLA-A*02:01-positive metastatic uveal melanoma (mUM). However, outside the pivotal study, limited data for tebentafusp a...
Eve Merry,Charlie Gourley
Eve Merry
Exploiting DNA damage repair (DDR) vulnerabilities has become a major focus in cancer drug development following the clinical success of poly (ADP-ribose) polymerase (PARP) inhibitors. Beyond PARP, inhibitors of multiple other DDR proteins ...
Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis [0.03%]
基于体重的派姆单抗给药剂量为每6周4mg/kg可导致低于获批剂量的暴露量且疗效尚未确定：基于药代动力学模型的模拟分析
Mallika Lala,Aditya Bardia,Antonio Calles et al.
Mallika Lala et al.
Background: Pembrolizumab is approved globally at a dose of 200 mg every 3 weeks (Q3W) or 400 mg every 6 weeks (Q6W) intravenously (IV). These dosing recommendations are based on established regimens that have demonstrate...
Two Phase II Trials of Adavosertib, a Wee1 Inhibitor with Docetaxel or Carboplatin plus Pemetrexed in Non-small-cell Lung Cancer [0.03%]
两项II期试验：评估Wee1抑制剂adavosertib联合多西他赛或卡铂+培美曲塞治疗非小细胞肺癌患者的疗效和安全性研究
Melissa L Johnson,Shaker R Dakhil,J Thaddeus Beck et al.
Melissa L Johnson et al.
Background: Adavosertib is a highly selective, small molecule Wee1 inhibitor that sensitizes tumor cells to cytotoxic agents. Objective: ...
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study [0.03%]
关于EGFR外显子20插入突变型非小细胞肺癌患者在III期PAPILLON研究中，amivantamab-化疗与治疗交叉及其他结果终点的关系分析
Rachel E Sanborn,Caicun Zhou,Ke-Jing Tang et al.
Rachel E Sanborn et al.
Background: In the PAPILLON study, first-line amivantamab-chemotherapy in epidermal growth factor receptor (EGFR) exon 20 insertion-mutated non-small cell lung cancer demonstrated significantly prolonged progression-free ...
The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis [0.03%]
β受体阻滞剂与免疫检查点抑制剂在肿瘤患者中疗效和安全性的系统评价和 meta 分析
Kota Tokunaga,Yu Fujiwara,Reo Omori et al.
Kota Tokunaga et al.
Background: Immune checkpoint inhibitors (ICIs) are now standard for various cancers, and preclinical studies suggest beta-blockers (BBs) may boost the efficacy of ICIs. However, prior clinical studies had small sample si...
Real-World Outcomes of Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma: A National Population-Based Cohort Study [0.03%]
伊匹单抗联合尼伏单抗治疗转移性肾细胞癌的现实世界结局：一项基于全国人群的队列研究
Chin Hang Yiu,Adrian Lee,Christine Y Lu
Chin Hang Yiu
Introduction: Immune checkpoint inhibitors are a standard first-line treatment for metastatic renal cell carcinoma (RCC), with combination ipilimumab and nivolumab (ipi-nivo) widely recommended. However, real-world data o...
Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis [0.03%]
奥希替尼与其他EGFR酪氨酸激酶抑制剂的心脏毒性谱比较：真实世界中的发病率分析
Zaid Muhanna,Muntaser Al Zyoud,Ahmad Issa et al.
Zaid Muhanna et al.
Background: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the standard first-line therapy for EGFR-mutant non-small cell lung cancer (NSCLC). Emerging evidence s...
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas [0.03%]
一项有关卢伐替尼治疗I型神经纤维瘤病相关无法切除的丛状神经纤维瘤的Ⅰ期临床研究
Xiaojie Hu,Zhuli Wu,Jinhu Wang et al.
Xiaojie Hu et al.
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by plexiform neurofibromas (PNs), which are present in 20-60% of NF1 and may cause potentially life-threatening complications. Complete surgic...